From: The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy
Control group (n = 142) | Cooling group (n = 40) | P-value | |
---|---|---|---|
Age (min-max) | 59.7 ± 11.5 (35–84) | 56.5 ± 10.4 (32–77) | 0.144 |
Cancer type | Ovarian (n = 80) Cervical (n = 14) Endometrial (n = 48) | Ovarian (n = 23) Cervical (n = 9) Endometrial (n = 8) | 0.053 |
Regimen | TC ± BV (n = 137) TP (n = 2) TAC or TEC (n = 3) | TC ± BV (n = 35) TP (n = 5) | 0.004 |
Concomitant platinum | CBDCA (n = 140) CDDP (n = 2) | CBDCA (n = 35) CDDP (n = 5) | 0.006 |
Cycle | 5.9 ± 0.4 | 5.9 ± 0.4 | 0.624 |
Body-surface area (m2) | 1.526 ± 0.151 | 1.483 ± 0.127 | 0.233 |
Initial PTX dose (mg/m2) | 170.2 ± 6.9 | 171.2 ± 8.4 | 0.944 |
Cumulative PTX dose (mg/m2) | 997.4 ± 78.9 | 1010.1 ± 95.1 | 0.483 |
Cumulative Platinum dose (mg/m2) | CBDCA; 2291.3 ± 391.7 CDDP; 324.8 ± 34.3 | CBDCA; 2332.2 ± 301.6 CDDP; 295.7 ± 5.5 | 0.565 0.311 |